Dr. Chalermchai revealed that molnupiravir (Molnupiravir) will be reduced 88 times from 23,100 baht to 264 baht per course.
Today (30 Oct. 21), Dr. Chalermchai Boonyaleephan, Deputy Chairman of the Senate Public Health Commission, posted a message via Facebook Chalermchai Boonyaleepun about Molnupiravir. (Molnupiravir)
By stating that good news !! big pharmaceutical company Molnupiravir Patent Free Makes Country Poor will be able to use the drug cheaper 88 times from 23,100 baht to 264 baht per course
Very good news for middle-income and poor countries. An agreement was announced between MSD (Merck&Co., Inc.) and Ridgeback Biotherapeutics. and Emory University
To not charge a patent for the new antiviral drug Molnupiravir, it entered into an agreement with the WHO-sponsored MPP (The Medicine Patent Pool), a public health agency.
such agreement It is the first agreement on drugs and technology for COVID-19.
It is important that Two companies and one university will not apply for a patent on such antiviral drugs. make the country low income and middle income 105 countries and more than 50 difficult companies
Companies in that country are able to produce Molnupiravir on their own, which has dramatically reduced the price per course. From 23,100 baht (700 USD) to only 264 baht ($8), down more than 87.5 times.
on condition that not charging for such patents It will continue as long as the World Health Organization has declared COVID-19. is an epidemic of the world (Public Health Emergency of International Concern). The signing of the agreement took place on October 27, 2021.
Merck executives have released a statement saying: Founded more than 130 years ago, the company is primarily committed to researching and developing medicines and medical supplies to help humanity.
The president of Emory University stated that the university has a policy to serve humanity or to serve society.
Ridgeback chief executive said the deal It is a prime example of the cooperation that will make the world’s health system better.
MPP executives said it was the first deal related to COVID-19 in the past. not expensive, such as AIDS drugs Hepatitis C virus medication and medicines to treat tuberculosis, etc.
Molnupiravir is an improved drug. by Emory University and licensed to Ridgeback and Merck as a patent to continue production. Code-named MK 4482 and EIDD 2801, they act against viral proliferation.
In Phase Three Research It can reduce the number of hospitalized patients by up to 50% in mild or moderately ill patients. without death
It is currently in phase three trials. and has submitted an Emergency Use Approval (EUA) to the USFDA and the European Agency (EMA) if approved. It will be the world’s first drug. that acts directly against the virus that causes COVID-19 and is considered very good news who owns and holds a patent on the said drug It’s a very big decision in the business of not paying for new drug patents that can make a lot of money.
make 105 countries around the world This drug can be accessed at a price that is more than 88 times cheaper.
If companies related to drugs and pharmaceuticals has implemented the same policy that will make more than half of the world’s people in poor and middle-income countries have the opportunity to receive quality treatment and likely to significantly reduce mortality This is a concrete reduction in human inequality.
The author expresses his appreciation and gratitude. with two companies and one university that work together to make good and beautiful things happen in this world.”
Image from AFP/Chalermchai Boonyaleepun
